
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is a clinical-stage biopharmaceutical company with a strong pipeline and differentiated therapeutic platforms. While competition in the HER2-targeted therapy market is a concern, potential approvals of zanidatamab and other pipeline assets could lead to significant revenue growth. However, regulatory risks must be considered as delays or failures to gain approval could impact the company's valuation.
Bears say
Zymeworks is facing regulatory and clinical risks as it advances its pipeline, with potential catalysts including December 2026 US Phase 1 approval of zanidatamab for GEA and future interim OS findings, potential partner JAZZ's global Ziihera approval in August 2026, ZW209's IND submission in mid-2026, and recent data being encouraging. Also, a sum-of-the-parts based DCF yields a $3.28B total firm value, with a $58 price target and various positive catalysts and competitive risks affecting the expected value.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares